Tredje AP fonden Purchases 21,810 Shares of Henry Schein, Inc. (HSIC)
Tredje AP fonden grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 173.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,400 shares of the company’s stock after buying an additional 21,810 shares during the quarter. Tredje AP fonden’s holdings in Henry Schein were worth $2,820,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Intrust Bank NA raised its position in shares of Henry Schein by 1.1% during the 2nd quarter. Intrust Bank NA now owns 1,219 shares of the company’s stock worth $223,000 after buying an additional 13 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of Henry Schein by 4.0% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 14,859 shares of the company’s stock worth $2,719,000 after buying an additional 566 shares in the last quarter. Bradley Foster & Sargent Inc. CT raised its position in shares of Henry Schein by 2.1% during the 2nd quarter. Bradley Foster & Sargent Inc. CT now owns 33,106 shares of the company’s stock worth $6,059,000 after buying an additional 690 shares in the last quarter. Steinberg Global Asset Management raised its position in shares of Henry Schein by 100.0% during the 3rd quarter. Steinberg Global Asset Management now owns 19,412 shares of the company’s stock worth $1,592,000 after buying an additional 9,706 shares in the last quarter. Finally, Comerica Bank raised its position in shares of Henry Schein by 10.6% during the 2nd quarter. Comerica Bank now owns 21,833 shares of the company’s stock worth $4,054,000 after buying an additional 2,101 shares in the last quarter. Institutional investors own 91.75% of the company’s stock.
HSIC has been the topic of a number of recent analyst reports. Credit Suisse Group restated a “hold” rating and set a $87.50 price target on shares of Henry Schein in a research report on Tuesday, August 29th. Jefferies Group restated a “hold” rating and set a $88.50 price target on shares of Henry Schein in a research report on Thursday, September 28th. Zacks Investment Research downgraded shares of Henry Schein from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Robert W. Baird set a $95.00 price target on shares of Henry Schein and gave the stock a “buy” rating in a research report on Thursday, October 19th. Finally, Northcoast Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 price target on the stock in a research report on Monday, August 7th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $88.36.
Henry Schein, Inc. (HSIC) opened at $71.21 on Tuesday. The stock has a market cap of $11,090.40, a P/E ratio of 19.82, a PEG ratio of 1.99 and a beta of 0.99. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30. Henry Schein, Inc. has a 52 week low of $65.28 and a 52 week high of $93.50.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). The business had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.84 EPS. research analysts expect that Henry Schein, Inc. will post 3.6 earnings per share for the current fiscal year.
Henry Schein declared that its board has authorized a stock repurchase program on Monday, September 18th that permits the company to repurchase $400.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 6.3% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board of directors believes its stock is undervalued.
In other news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $70.76, for a total value of $410,124.96. Following the transaction, the director now owns 48,172 shares of the company’s stock, valued at approximately $3,408,650.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the transaction, the senior vice president now directly owns 17,841 shares in the company, valued at approximately $3,077,750.91. The disclosure for this sale can be found here. Insiders own 1.19% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.